[go: up one dir, main page]

LT3576740T - Vėžio gydymas - Google Patents

Vėžio gydymas

Info

Publication number
LT3576740T
LT3576740T LTEPPCT/EP2018/052694T LT18052694T LT3576740T LT 3576740 T LT3576740 T LT 3576740T LT 18052694 T LT18052694 T LT 18052694T LT 3576740 T LT3576740 T LT 3576740T
Authority
LT
Lithuania
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
LTEPPCT/EP2018/052694T
Other languages
English (en)
Inventor
Kim STUYCKENS
Juan PEREZ RUIXO
Peter DE PORRE
Anjali AVADHANI
Yohann LORIOT
Arlene SIEFKER-RADTKE
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3576740(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of LT3576740T publication Critical patent/LT3576740T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
LTEPPCT/EP2018/052694T 2017-02-06 2018-02-02 Vėžio gydymas LT3576740T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
LT3576740T true LT3576740T (lt) 2023-08-10

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/052694T LT3576740T (lt) 2017-02-06 2018-02-02 Vėžio gydymas

Country Status (25)

Country Link
US (2) US11077106B2 (lt)
EP (2) EP4286005A3 (lt)
JP (3) JP2020505425A (lt)
KR (2) KR20190110581A (lt)
CN (1) CN110198716A (lt)
AU (2) AU2018216969B2 (lt)
BR (1) BR112019016043A2 (lt)
CA (1) CA3049737A1 (lt)
DK (1) DK3576740T3 (lt)
ES (1) ES2953005T3 (lt)
FI (1) FI3576740T3 (lt)
HR (1) HRP20230697T1 (lt)
HU (1) HUE062453T2 (lt)
IL (1) IL268463A (lt)
JO (1) JOP20190190A1 (lt)
LT (1) LT3576740T (lt)
MX (2) MX2019009304A (lt)
PH (1) PH12019501885A1 (lt)
PL (1) PL3576740T3 (lt)
RS (1) RS64778B1 (lt)
SG (2) SG10202105110VA (lt)
SI (1) SI3576740T1 (lt)
SM (1) SMT202300233T1 (lt)
TW (1) TWI874925B (lt)
UA (1) UA126336C2 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
SMT202200177T1 (it) 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA54932A (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica Nv Traitement contre le cancer
WO2020205493A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3946340A1 (en) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2021220285A1 (en) * 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
PH12019501885A1 (en) 2020-06-29
EP3576740B1 (en) 2023-06-14
BR112019016043A2 (pt) 2020-03-31
CA3049737A1 (en) 2018-08-09
JOP20190190A1 (ar) 2019-08-04
DK3576740T3 (da) 2023-07-24
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
JP2020505425A (ja) 2020-02-20
HRP20230697T1 (hr) 2023-10-13
US20200022976A1 (en) 2020-01-23
HUE062453T2 (hu) 2023-11-28
JP2025024064A (ja) 2025-02-19
US11077106B2 (en) 2021-08-03
EP4286005A3 (en) 2024-03-06
ES2953005T3 (es) 2023-11-07
AU2018216969B2 (en) 2024-04-11
EP3576740A1 (en) 2019-12-11
AU2018216969A1 (en) 2019-07-25
SI3576740T1 (sl) 2023-10-30
SG10202105110VA (en) 2021-06-29
FI3576740T3 (fi) 2023-08-31
AU2024201871A1 (en) 2024-04-11
EP4286005A2 (en) 2023-12-06
MX2022007955A (es) 2022-07-27
PL3576740T3 (pl) 2023-09-11
JP7668777B2 (ja) 2025-04-25
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
IL268463A (en) 2019-09-26
SMT202300233T1 (it) 2023-09-06
TWI874925B (zh) 2025-03-01
KR20190110581A (ko) 2019-09-30
MX2019009304A (es) 2019-09-19
CN110198716A (zh) 2019-09-03
RS64778B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PT3576740T (pt) Tratamento de cancro
IL263123A (en) Cancer treatments
IL259996A (en) Combinations for cancer treatment
SG10202105110VA (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL247859A0 (en) Cancer treatment
ZA201707024B (en) Cancer treatment composition
IL274626A (en) Cancer treatment
IL260814A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL274748A (en) Improved cancer treatment
GB201522433D0 (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201718985D0 (en) Treatment
GB201704909D0 (en) Cancer therapy
GB201819920D0 (en) Cancer treatment
GB201711855D0 (en) Cancer therapy
GB201713852D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy